Drugmaker VIVUS (NASDAQ:VVUS) reported its fourth-quarter earnings after the closing bell on Monday. Shares traded down 12% today; investors were clearly not impressed with the results.

Sales of the company's obesity drug Qsymia were the primary focus of the report, but what else should investors be paying attention to when they analyze VIVUS' quarter? In this video, health care analyst Max Macaluso discusses three essential topics that investors need to consider.